



# Index to Volume 21

## Subject Index

- A
- Acceptor specificities, 397(O14)
- Actin filaments, depolymerization of, 105
- Acute myeloblastic leukemia, 452
- Adenosine 3',5'-cyclic monophosphate.  
*See* cAMP
- Adhesion. *See also* Anti-adhesion therapy  
and differentiation of HL60 cells, 407(P26)  
force, 111  
glycan-glycan, 117  
GSL-dependent, 128–130  
species-specific, 117  
vesicle, 166–168
- Advanced Industrial Science and Technology  
(AIST) in Japan. *See* Glycosyltransferase,  
genes in yeast
- Affinity of sialyltransferase inhibitors, 205–218
- AFM. *See* Atomic force microscopy
- Agglutinin  
*Dolicos biflorus* (DBA), 42  
*Garanthas nivalis*, 31  
Hemagglutinin  
*Lotus tetragonolobus* (LTA), 41  
*Maackia amurensis*, 451  
peanut, 451  
*Ricinus communis*, 409(P31)  
*Sambucus nigra*, 451  
soy bean, 451  
*Vicia villosa*, 451
- Aggrecan  
deficient mutants, 335  
expression in vivo, 337  
in developing brain, 332
- Aggregation  
assays, 113  
PMN, 81, 82
- AIST in Japan. *See* Glycosyltransferase, genes  
in yeast
- Albumin  
bovine serum, 97, 149, 361  
human serum, 251
- Alkaline phosphatase, 487
- ALPase. *See* Alkaline phosphatase
- Alpha modified Eagle's medium without riboside  
and deoxyriboside, 479
- Alpha-MEM, 479
- Alzheimer's disease, 25
- 6-aminogalactose, 461
- Aminopeptidase, 25
- AML. *See* acute myeloblastic leukemia
- Amyloid precursor protein, 25
- Analogues of monoglucosylated glycan chain,  
257–264
- Analytical methods, for sialyltransferase  
inhibitors synthesis, 211
- Anti-adhesion therapy  
general approach, 475  
influenza viruses, 471–472  
ligand choice, 471  
multimeric PAA conjugates, 472  
principle of, 471  
self-assembled molecules, 473  
virus promoted association, 475
- Antibodies, 100  
anti-Le<sup>X</sup>, 41  
HNK-1, 54  
monoclonal, , 115, 451, 394(O6)  
monoclonal antibodies specificity against  
*Schistosoma mansoni* antigen, 402(P10)
- Antibodies and nano-biosensors  
antibody-bound gold nanowire arrays, 487  
attachment to electrode surface, 491  
binding to gold patterns, 490  
immobilization, 491  
removal from GNW, 491
- Antibody-antigen recognition, 120
- Antibody-bound gold nanowire arrays, 487
- Anticancer drug rViscumin, 409(P32)
- Anti-corrosive polysaccharides, structural  
analysis of, 416(P51)
- Antigens  
carcinoembryonic, 33  
carbohydrate (Lewis X), 41  
ECMA-2, 42  
fucosylated, 394(O6)  
GPI-anchored SAG, 400(P3)  
Lewis, 395(O8)  
Lewis X, 41, 149  
*Schistosoma mansoni*, 402(P10)  
stage-specific embryonic antigen (SSEA), 149  
SSEA-1, 41, 42  
SSEA-3, 41, 42  
SSEA-4, 41, 42  
viral, 394(O5)
- Anti-Le<sup>X</sup> antibody, 41
- Anti-sense S oligonucleotide. *See* ASMMP-2
- Apoptosis, 315–325  
in *Saccharomyces cerevisiae*, 407(P25)  
in GSD, 295, 299  
induced by glutamate excitotoxicity, 305–312  
KCl induced, 305  
U937 cell, 32
- APP mutant, 26
- Arabidopsis, glycoproteome profiling in,  
398(O18)
- Arteries, 361
- Articular chondrocyte transplants, 412(p38)
- Artificial glycoprotein, 69, 70, 73
- Artificial seawater, 111
- Arylsulfatase A (ASA), 403(P13)
- ASGPr. *See* Asialoglycoprotein receptor
- Asialo biantennary complex-type  
oligosaccharide, 377
- Asialoglycoprotein receptor, ligands of  
binding studies with biotinylated cluster  
glycosides, 227  
materials and methods, 235  
flow cytometry analysis, 227, 240  
liquid-phase synthesis, 238  
solid-phase synthesis, 236, 238  
synthesis of, 227  
biotin-labelled GalNAc ligands, 228  
solid-phase synthesis, 228, 230  
solution phase chemistry, 230
- ASMMP-2, 435
- Asn(GlcNAc), 377
- Asparagine (Asn), 3
- Asparagine linked  
 $\alpha$ -(2,3)-sialyloligosaccharides, 243  
oligosaccharide, 243  
protein glycosylation, 479
- Aspergillus fumigatus*, UDP-Galactopyranose  
Mutase in, 414(P45)
- ASTF. *See* Asialo biantennary complex-type  
oligosaccharide
- Asymmetric cell division, 317–319
- Asymmetric synthesis of sialyltransferase  
inhibitors, 208–210, 221–225
- Atomic force microscopy, 111, 113, 125, 149, 152
- Autoaggregation, 125  
human teratocarcinoma, 129  
mouse teratocarcinoma, 126, 127
- B
- B3GALT7 gene  
cloning, 267–268  
expression in prokaryote, 271  
northern blot analysis, 268  
plasmid expression, 268  
related to  $\beta$ 1,3-galactosyltransferase and  
 $\beta$ 1,3-N-acetylglucosaminyltransferase  
family, 267  
RT-PCR, 268  
tissue distribution, 271
- BACE1 ( $\beta$ -secretase), 25. *See also* ST6Gal I  
( $\alpha$ 2,6-sialyltransferase)
- Bacteria, 471
- baculovirus infected insect cells, 413(P41)
- Basigin, 43

- BD. *See* Blue dextran
- Benzyl mannose, 396(O12)
- Biglycan, 361
- Binding
  - affinity of sialyltransferase inhibitors, 205–218
  - protein, 125
  - specificities of *helicobacter pylori* adhesins by glycoconjugate arrays, 397(O15)
- Biocatalytic properties of recombinant Sucrose Synthase 1, 413(P44)
- Bioinformatics pipeline for genome-wide analysis of glycoproteins, 415(P50)
- Biological activity, N-glycosylated eel calcitonin derivatives, 377
- Biomphalaria glabrata with Schistosoma mansoni, 395(O7)
- Bioplex, 227
- Biosensor. *See* Nano-biosensor
- Biosynthesis
  - endogenous N-glycolylneuraminate, 416(P53)
  - N-glycans, 394(O4)
  - O-glycans, 394(O4)
- Biotin-labelled galnac ligands, synthesis of, 228
- Biotinylated cluster glycosides, 227
- Bivalent cation, 125, 132
- Blood
  - coagulation factor IX carrying xylosyl-glucose, 197–202
  - vessels, human umbilical cord, 361
- Blotting, Western. *See* Western blotting
- Blue dextran, 361
- Bone marrow cells, 451. *See also* CD34 progenitors, from peripheral blood and bone marrow
- Botulinum neurotoxin (BoNT)
  - binding, 289, 291
  - GSL, 287, 289
  - function, 291
  - interaction, 290
- Bovine serum
  - Albumin (BSA), 97, 149, 361
  - fetal (FBS), 305–312
- Brain, 53
- Brain development
  - aggreccan
  - deficient mutants, 335
  - expression in vivo, 337
  - in developing brain, 332
  - proteoglycans in, 329–331
  - of mouse, postnatal, 404(P16)
- BSA (bovine serum albumin), 97, 149, 361
- C
- C. elegans. *See* Caenorhabditis elegans
- C4S. *See* Chondroitin 4-sulfate
- C5-epimerase, 47
- C6S. *See* Chondroitin 6-sulfate
- Ca<sup>2+</sup>
  - homeostasis, 305–312
  - ions effect on GM3-Gg3 interaction, 146
  - carbohydrate-carbohydrate interaction strength by increasing, 118
- CAA antigen, 402(P10)
- Caenorhabditis elegans, 35, 63
  - posttranslational modifications in, 406(P21)
- Calcitonin, 377
- Calcitonin derivatives, artificially N-glycosylated, 377–385
  - biodistribution, 380
  - chemo-enzymatic synthesis and structure-activity study of, 377
  - circular dichroism (CD) measurement, 380
  - hypocalcemic activity, 380
  - neuraminidase treatment, 379
  - receptor binding assay, 380
  - transglycosylation of disialo biantennary complex-type oligosaccharide, 378
  - with complex type oligosaccharide asialo biantennary, 377
  - disialo biantennary, 377, 378
- Calcitonin receptor, 380
- Calcium, 89, 295
  - calcium-and magnesium-free tris-buffered seawater (CSW), 111
  - influx, 407(p26)
- Calcium ions
  - glycolipids complex, 170
  - Le<sup>x</sup>-Le<sup>x</sup> recognition with, 170
- CALEB, 53
- Calnexin (CNX), 69, 257–264
- Calorimetry, isothermal titration, 257, 263, 264
- Calreticulin (CRT), 69, 257, 263
- CAM, 125. *See also* Cell adhesion
- cAMP, 479
  - dependent protein kinase, 479
  - dependent protein phosphorylation, 479
- CaMV. *See* Cauliflower mosaic virus
- Cancer cells. *See also* Carcinoma cells
  - breast cancer, 408(P28)
  - glycosphingolipid metabolism in, 315–325
- Cancer therapy, 322
- Candida albicans, 3
- Capillary-scale high-performance anion-exchange chromatography with pulsed amperometric detection, 401(P8)
- Capillary nano-electrospray (nanoESI), 398(O17)
- CAPS, 361
- Carbohydrate, 63, 179–194
  - CRD, 79, 503
  - dependent cell adhesion, 133
  - markers, 41
  - mediated self-recognition of marine sponge cells, 402(P11)
  - unmasked, 197–202
- Carbohydrate antigens
  - expression on early embryonic cells, 42
  - expression on stem cells, 41
  - function of, 43
- Carbohydrate-binding site, 471
- Carbohydrate-carbohydrate interaction, 125. *See also* Protein-to-protein interaction
- AFM measurements of, 118
- based cell adhesion, features of
  - bivalent cation requirement, 132
  - clustering proper orientation, 131
  - negative interaction, 132
  - reaction velocity, 132
  - specificity, 131
  - synergistic effects of CCI with PPI, 132
- between lactose and GM<sub>3</sub>, 89
- binding affinity and specificity of comparable to CPI or PPI, 130
- glycanotechnology-mediated, 149
  - anti-adhesive therapy, 158–160
  - Gold GNP, 155
  - Le<sup>x</sup>GNPs, 156
  - Le<sup>x</sup>-Le<sup>x</sup> interaction, 156
  - neoglycoconjugates, 151
  - studying and evaluating, 152
- initiating cell-cell recognition, 111
- strength by increasing Ca<sup>2+</sup>, 118
- through glycosynapse as basis of cell recognition, 125
- Carbohydrate-carbohydrate recognition, 111, 165
- Carbohydrate of keyhole limpet hemocyanin (KLH), 405(P20)
- Carbohydrate-protein interactions, 407(P24)
- Carbohydrate recognition domain (CRD), 79, 503
- Carbohydrate recognition of IL-2, 33
- Carcinoembryonic antigen (CEA), 33
- Carcinoma cells. *See also* Cancer cells
  - embryonal, 41
  - mammary, 416(P53)
- Cardiomyopathy, 412(P39)
- Caspr. *See* Contactin-associated protein
- Cauliflower mosaic virus 275
- CBS. *See* Carbohydrate-binding site
- CBS. *See* Cerebroside sulfate
- CCI. *See* Carbohydrate-carbohydrate interaction
- CD. *See* Circular dichroism
- CD164 (MGC-24v) marker, 41, 43
- CD34 marker, 41, 43
- CD34 progenitors, from peripheral blood and bone marrow
  - CD34+ HPC, separation of, 452
  - cell lines, 452
  - cell surface sialylation, 451
  - ecto-sialyltransferase activity, 451
  - flow cytometric detection of cell surface sialylation, 452
  - lectin staining, 453
  - immunoprecipitation and Western blotting of, 453
- CD43 cells, 451
- CD45 cells, 451
- CD75s-bearing glycoproteins, 409(P32)
- CD75s-gangliosides and CD75s-bearing glycoproteins, 409(P32)
- CD75s-gangliosides, 409(P32)
- CDG. *See* Congenital defects of glycosylation
- cDNA
  - expression, 43
  - encoding human, 412(P40)
  - NGC, 55
  - pipe, 50
  - Sd, 50
  - transfection experiments, 41
- CEA (carcinoembryonic antigen), 33
- CE-ESI-TOF-MS, 399(O19)
- CelC14, 89
- Cell adhesion, 89, 165
- CCI based, 125
  - binding affinity and specificity of comparable to CPI or PPI, 130

- characteristic features and requirements of, 131
- glycoconjugates organization involved in *trans*- and *cis*-CCI, 133
- mediated by *cis*-CCI, 130–131
- mediated by *trans*-CCI, 126–130
- cell-cell adhesion, 112, 117
- molecule (CAM), 125
- specific proteoglycan-mediated, 120
- with concurrent signal, 125, 133
- Cell-cell aggregation, 115, 117
- Cell-cell recognition, CCI for, 111
- materials and method, 112
- AFM, 113
- aggregation assays, 113
- analytical methods, 113
- binding of cells and glycans to glycan-coated plates, 113
- long term EDTA-treatment of sponge proteoglycans, 113
- results
- carbohydrate-carbohydrate interaction, 118
- species-specific adhesion, 117
- species-specific aggregation, 115, 117
- species-specific carbohydrate composition of proteoglycan molecules, 118
- Cell-cycle arrest, 315–325
- Cell division, asymmetric, 317–319
- Cell migration, 429
- Cell migration and ECM invasion
- curcumin role in, 435
- MMP-2 role in, 435
- OPN enhancing, 434
- Cell migration assay, 431
- Cell recognition. *See also* Cell-cell recognition, CCI for
- CCI through glycosynapse as basis of, 125
- cell-glycan recognition, 115
- specific proteoglycan-mediated, 120
- Cell specific glycoproteome profiling in Arabidopsis, 398(O18)
- Cell surface glycans, 503
- Cell surface growth factor receptors and ECM receptors, 12. *See also* Integrins
- Cell surface proteoglycan, 111
- Cell surface sialylation, 451, 452
- Cell wall, 75
- Central nervous system, 97
- Ceramide, 315–325, 461
- galactosyl, 89
- galactosylceramide, 97
- galactosyltransferase, 97
- lactosyl
- Cerebellar granule neurons from GM2/GD2 synthase-null mice, susceptibility to apoptosis induced by glutamate excitotoxicity and elevated KCl
- animal and cell culture, 306
- cell survival determination, 307
- rescue by GM1 and LIGA20, 305–312
- Cerebellar granule neurons, 305–312
- Cerebroside sulfate, 89
- Cerebroside sulfotransferase, 59
- in baculovirus infected insect cells, 413(P41)
- Cesium bromide, 361
- Cetyltrimethylammonium bromide, 275
- CGL. *See* Cortical granule lectin
- CGN. *See* Cerebellar granule neurons
- CGT, 393(O2)
- Chaperones, 396(O10)
- Chemo-enzymatic synthesis and structure-activity study of artificially N-glycosylated eel calcitonin. *See* Calcitonin derivatives, artificially N-glycosylated
- Chemoenzymatic synthesis of asparagine-linked  $\alpha$ -(2,3)-sialyloligosaccharides, 243–250
- Chicken acidic leucine-rich EGF-like domain containing brain protein (CALEB), 53
- Chinese hamster ovary cell, 479
- Chinese Hamster Ovary cell deficient in UDP-Xylose Synthase (USX), 417(P56)
- chip electrospray mass spectrometry in structural glycobiology, 398(O17)
- ChipESI, 404(P15)
- CHO. *See* Chinese hamster ovary cell
- Cholera B subunit. *See* Ctx B
- Cholesterol, 97
- Chondrocyte transplants, 412(P38)
- Chondroitin 4-sulfate, 361
- Chondroitin 6-sulfate, 361
- Chondroitin sulfate (CS), 53. *See also* Dermatan sulfate
- characterization of human umbilical cord blood vessels, 361, 363
- glycosylation, 54
- proteoglycan (CSPG), 53, 329, 361
- CHPAEC-PAD, 401(P8)
- Chromatography
- flash (FC), 211
- frontal affinity, 35
- HPAEC, 401(P8)
- HPLC, 275, 461
- liquid column (LC), 31
- thin layer, 461
- weak affinity, 149
- Circular dichroism, 197, 199, 202, 377, 380
- cis* interaction, 125
- cis*-CCI based cell adhesion, 130–131. *See also* *Trans*-CCI based cell adhesion
- Class I viral antigens, 394(O5)
- Class II viral antigens, 394(O5)
- Cliona* proteoglycan, 120
- Cloning and tissue distribution of human B3GALT7 gene. *See* B3GALT7 gene
- Clostridium botulinum, 287
- Cluster glycoside, 227
- CMP-5-F-Neu. *See* Cytidine-5'-monophospho-5-fluorescein-thioureido-N-acetyl-neuraminic acid
- CMP-NeuAc, 343
- generation, 351
- synthesis pathways, 349
- CNS. *See* Central nervous system
- CNS proteoglycans. *See* Brain development, proteoglycans in
- CNX (calnexin), 69
- Complex type, 243
- Complex-type oligosaccharide
- asialo biantennary, 377
- disialo biantennary, 377, 378
- Complexation, 165
- Compositional analysis, PG
- GAG chain disaccharide, 364
- hexosamine, 363
- Concurrent signal transduction, cell adhesion with, 133
- Congenital defects in mucin type O-glycosylation, 405(p19)
- Congenital defects of glycosylation, 394(O4), 405(P19)
- Congenital muscular dystrophy, 3–6. *See also* O-mannosyl glycans
- Fukuyama-type congenital dystrophy (FCMD), 5, 6
- muscle-eye-brain disease (MEB), 5–6
- Walker-Warburg syndrome (WWS), 5–6
- Conjugates synthesis
- DSS, 251, 255
- HSA, 251, 255
- Contactin-associated protein, 97
- Cortical granule lectin, 443
- CPI. *See* Carbohydrate-protein interaction
- CRD. *See* Carbohydrate recognition domain
- CRD. *See* C-type lectin domain
- CRT. *See* Calreticulin
- Crystal structure of FimH lectin domain, 398(O16)
- CS. *See* Chondroitin sulfate
- CsBr, 361
- CSPG. *See under* Chondroitin sulfate
- CST. *See* Cerebroside sulfotransferase
- CSW. *See under* Calcium
- CT. *See* Calcitonin
- CTAB. *See* Cetyltrimethylammonium bromide
- CTLL-2 cell proliferation, 33
- CTn-XXX, 377
- CT-R. *See* Calcitonin receptor
- Ctx B conjugated with
- fluorescein isothiocyanate, 305–312
- horseradish peroxidase, 305–312
- Ctx B-FITC, 305–312
- Ctx B-HRP, 305–312
- CT-XXX, 377
- C-type lectin, 395(O8), 406(P23), 416(P52)
- C-type lectin domain (CRD), 449
- Curcumin
- inducing apoptotic morphology in OPN treated cells, 438
- role in cell migration and ECM invasion, 435
- Curcumin blocking OPN-induced
- MT1-MMP expression, 433
- NF- $\kappa$ B activation, 436
- Cutis laxa patients, 394(O4)
- Cyclic voltametry (CV), 487
- 3-(cyclohexylamino)propanesulfonic acid, 361
- Cysteine, 395(O9)
- Cytidine-5'-monophospho-N-acetylneuraminic acid, 343
- Cytidine-5'-monophospho-5-fluorescein-thioureido-N-acetyl-neuraminic acid, 451
- Cytokine, carbohydrate recognition by, 31
- Cytoskeleton organization, 9. *See also* Integrins
- Cytotoxicity, MBP-dependent cell-mediated, 79

- D
- d $\beta$ 4GalTI glycan, 65–68
- D. rerio. *See* Danio rerio, galectins in
- Danio rerio*, galectins in, 503–518
- binding properties, 504–505
  - biochemical properties, 504
  - biological role in development and innate immunity, 503, 507–512
  - evolutionary aspects, 505–506
  - protein structure and gene organization, 505
  - subcellular localization and secretion, 506
- Days *in vitro*, 305–312
- DC-SIGN, 405(P18), 406(P23), 410(P33)
- DEAE. *See* Diethylaminoethyl
- Decasaccharide, monosialyl, 248, 249
- Decorin and biglycan, 361
- Deglycosylation, ERAD, 396(O12)
- Dendritic cell expressed C-type lectin MGL specifically interacts with terminal GalNAc residues, 416(P52)
- Depolymerization of actin filaments, 105
- compositional analysis, 363
  - Dermatan sulfate, 330. *See also* chondroitin sulfate
  - characterization of human umbilical cord blood vessels, 361
  - proteoglycan (DSPG), 361
- Detergent-insoluble glycosphingolipid-enriched microdomains, 97
- Deutero-reduction, 410(P34)
- dGal, 377
- D-galactose, 377
- dHS6ST. *See* *Drosophila* HS6ST
- Diabetic nephropathy and genetic variations in xylosyltransferase genes XT-I and XT-II in type 1 diabetic patients, 414(P46)
- Dichroism, circular, 377, 380
- Diethylaminoethyl, 361
- Diferuloylmethane. *See* Curcumin
- DIGs. *See* Detergent-insoluble glycosphingolipid-enriched microdomains
- Dilated cardiomyopathy, 412(P39)
- Dimethyl sulfoxide, 479
- 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide. *See* MTT
- Disialo biantennary complex-type oligosaccharide, 377, 378
- $\alpha$ -(2,3)-disialyl oligosaccharide, 248
- Disulfide bond pairings, 202
- Dithiobissuccinimidylundecanoate. *See* DSU
- DIV. *See* Days *in vitro*
- $\beta$ -D-galactosidase digestion of monosialyl decasaccharide, 248, 249
- D-mannose, 377
- $\alpha$ -D-mannosidase digestion of monosialyl octasaccharide, 249
- DMEM (Dulbecco's modified Eagle medium), 479
- DMF, 461
- DNA-binding, glycosylation role in, 409(P30)
- Dodecasaccharide, synthetic, 74
- Dolichyl monophosphate. *See* Dol-P
- Dolicos biflorus* agglutinin (DBA), 42
- Dol-P, 479
- Dol-P-Man, 479, 480
- Dol-P-Man synthase, 480
- activity in wild type and PKA deficient mutants, 483
  - functionally altered, 479
- Double-stranded RNA (dsRNA), 64
- dPAPS transporter, 65–68
- DPMS, 479
- DPPC (dipalmitoylphosphatidylcholine), 90
- Drgal1-L1, 503
- Drgal1-L2, 503
- Drgal1-L3, 503
- Drgal3, 503
- Drgal9-L1, 503
- Drosophila*
- orthologs of a human glycosyltransferase, 64
  - RNA interference knockdown system in, 63
  - TBLASTN search of, 64, 65
- Drosophila* HS2ST. *See also* Zebrafish HS6ST
- pipe* gene, 50
  - Sd* gene, 50
- Drosophila melanogaster* homologue of human
- histo-blood group P<sup>k</sup> gene, 411(P36)
- DS. *See* Dermatan sulfate
- DSPG. *See under* Dermatan sulfate
- dsRNA (double-stranded RNA), 64
- DSS-conjugation, 251, 255
- DSU, 487
- synthesis for nano-biosensor, 490
- DSU-SAM, 491, 493
- Dulbecco's modified Eagle medium, 305–312
- Dystroglycan, 3
- $\alpha$ -dystroglycan, glycosylation of, 5
- Dystrophy, muscular congenital, 3–6. *See also* O-mannosyl glycans
- Fukuyama-type congenital dystrophy (FCMD), 5, 6
  - muscle-eye-brain disease (MEB), 5–6
  - Walker-Warburg syndrome (WWS), 5–6
- E
- E. chrysanthemi* proteome, 401(P7)
- E. Coli*, 267, 398(O16), 413(P44), 487
- Early embryonic cells, carbohydrate antigens expression on, 42
- EC (embryonal carcinoma) cells, 41. *See also* Carbohydrate antigens
- EC 2.4.99.1, 451
- EC 3.2.1.18, 451
- ECD of glycoconjugate ions, 411(P35)
- ECM. *See* Extracellular matrix
- ECM invasion assay, 432
- ECMA-2 antigen, 42
- Ecto-sialyltransferase ST6Gal I, 451
- Edg-1/S1P1, N-glycosylation in, 497–500
- EDTA, 149, 361
- treatment of sponge proteoglycans, 113
- Eel calcitonin derivatives. *See* Calcitonin derivatives, artificially N-glycosylated
- EGF. *See* Epidermal growth factor
- EGF-like domain. *See* Epidermal growth factor-like domain
- EGFR. *See* Epidermal growth factor receptor
- EIS (electrochemical impedance spectroscopy), 487, 491, 494, 495
- Electrochemical impedance spectroscopy, 487, 491, 494, 495
- Electrode surface fabrication, for nano-biosensor, 489
- Electrophoretic mobility shift assay, 432
- Electrospray ionization (ESI), 31
- Electrospray-ionization ion-trap mass spectrometry (CHPAEC-ITMS), 401(P8)
- Embigin, 43
- Embryoglycan, 41. *See also* Carbohydrate antigens
- Embryonal carcinoma (EC) cells, 41. *See also* Carbohydrate antigens
- Embryonic stem cells, 41, 315–325
- EMSA. *See* Electrophoretic mobility shift assay
- Endogenous N-glycolylneuraminase biosynthesis in human mammary carcinoma cells, 416(P53)
- Endo-M, 377
- Endoplasmic reticulum, 257–264, 479
- Endothelial cells, 443
- TNF $\alpha$ -induced changes in glycosylation of, 404(P17)
  - umbilical vein, 405(P18)
- Endothelial differentiation gene, , 497–500
- Enzymatic defect, 295, 296
- Epidermal growth factor (EGF), 125
- Epidermal growth factor receptor, 125
- Epidermal growth factor-like domain CD spectrum, 199
- experimental, 200–202
  - solid-phase synthesis, 197–202
  - synthesis and conformational characterization, 197–202
- ER-associated degradation. *See* ERAD
- ER high-mannose-type oligosaccharides facile synthesis and partial structure of, 70
- synthesis of, 69
- ERAD, 69
- deglycosylation in, 396(O12)
- Erwinia chrysanthemi* proteome, 401(P7)
- ES. *See* Embryonic stem cells
- ESI, 398(O17)
- ESI-MS, 400(P4)
- ESI QTOF tandem MS and deutero-reduction, 410(P34)
- Ethanolamine, 31
- Ethylenediaminetetraacetic acid. *See* EDTA
- EtN. *See* Ethanolamine
- Excitotoxicity, glutamate, 305–312
- Exoplasmic leaflet of neuronal plasma membranes, gangliosides and proteins interactions, 461
- Expression and purification, human
- UDP-Xylose/UDP-GlcNAc transporter, 399(P2)
- Expression, NGC
- changes elicited by drug addiction and nerve injury, 55
  - tissue specific, 55
- Extracellular matrix, 9, 429, 503. *See also* MMP-2
- Extracellular matrices of human umbilical cord blood vessels, 361
- F
- Fabry disease, 299
- FAC. *See* Frontal affinity chromatography

- FAC/FD, 37  
 FACS. *See* Flow cytometry analysis  
 FBS. *See* Fetal bovine serum  
 FC. *See* Flash chromatography  
 FD. *See* Fluorescence detection  
 FDA. *See* Fluorescein diacetate  
 Fertilization, 503  
 Fetal bovine serum, 305–312  
 FGF. *See* Fibroblast growth factor  
 FGF-10, 49  
 FGFR-2b isoform, 49  
 FGFR-2c isoform, 49  
 Fibroblast growth factor, 31  
 Fibronectin, 125  
 Fibrotic degeneration of heart in dilated cardiomyopathy, 412(P39)  
 FimH lectin domain, 398(O16)  
 Fine structure, heparan sulfate, 49  
 Flash chromatography, 211  
 Flow cytometry analysis, 227, 240  
   cell surface sialylation, 452  
   lectin staining, 453  
 Fluorescein diacetate, 305–312  
 Fluorescence detection, 37 (FD). *See also* Structural glycomics (SG)  
 Fluorescent NeuAc-labeled surface glycoproteins, 453  
 2-fluorinated oligosaccharide, 257–264  
 Fluorine substituted oligosaccharide, synthesis of, 257–264  
 FN. *See* Fibronectin  
 Fourier transform infrared spectroscopy, 149  
 Fractionation, nuclear and cytoplasmic, 431  
 Frontal affinity chromatography, 35. *See also* Glycan profiling  
 FT-ICR MS, 400(P4), 404(P15)  
 FT-IR. *See* Fourier transform infrared spectroscopy  
 Fucose, 343, 149  
 Fucosylated antigens, 394(O6)  
 Fucosylation in insect cells, 348  
 Fucosyltransferases (FucT), 76, 78  
 FucT C3 activity in insect cells, 354  
 Fukuyama-type congenital dystrophy (FCMD), 5, 6  
 Functional glycomics, 35. *See also* Structural glycomics (SG)  
 FUT4 cDNA expression, 43  
 FUT6, 76  
 FUT-I expression controls binding of DC-SIGN to ICAM-2, 405(P18)  
 G  
 G protein-coupled receptor, 497–500  
 GAG. *See* Glycosaminoglycan  
 GAG chains, 363  
   disaccharide compositional analysis, 364  
   in proteoglycans, 329  
 GAL4-UAS system, 64  
 Galactolipids  
   in myelin, importance of, 98  
   role in oligodendrocytes and myelin, 98  
 Galactosamine. *See* GalN  
 Galactose, 149, 343  
   conjugated to bovine serum albumin (Gal-BSA), 97  
   D-galactose, 377  
 $\alpha$ -galactosyl antigen, 42  
 Galactosylation, 347  
 Galactosylceramide. *See* GalC  
 Galactosylceramide 3'-sulfotransferase, 97  
 Galactosyltransferase (GalT), 76, 343  
   ceramide, 97  
 Gal-BSA. *See under* Galactose  
 GalC, 89, 97, 393(O2)  
 GalC and SGC  
   act as ligands, 99  
   trans interactions between, 101  
 GalC/SGC  
   in OLS, 100  
   transmembrane signal transmission from, 101  
   containing liposomes, 102  
 GalCer, 89. *See also* LacCer  
 Galectin-1 like lectin 1, 503  
 Galectin-1 like lectin 2, 503  
 Galectin-1 like lectin 3, 503  
 Galectin-3 like lectin from *D. rerio*, 503  
 Galectin-9 like lectin from *D. rerio*, 503  
 Galectins in teleost fish, 503–518  
   binding properties, 504–505  
   biochemical properties, 504  
   biological role in development and innate immunity, 503, 507–512  
   evolutionary aspects, 505–506  
   protein structure and gene organization, 505  
   subcellular localization and secretion, 506  
 GalN, 361, 461  
 GalNAc (*N*-acetylgalactosamine), 3, 21. *See also* GlcNAc (*N*-acetylglucosamine)  
   ligands, 227  
   residues, 416(P52)  
 GalT. *See* Galactosyltransferase  
 Gangliosides, 287, 288, 315–325, 461  
 CD75s-gangliosides, 409(P32)  
 GM1, 305–312  
   and proteins interactions, in exoplasmic leaflet of neuronal plasma membranes, 461  
 Garanthas nivalis agglutinin, 31  
 Gaucher disease, 296  
 Gb4, 125  
 Gb5, 125  
 GD2-synthase knockout mice, 322–323  
 GdnHCl, 361  
 GDP-Fuc, 343  
 GDP-Man, 343  
 GEMs. *See under* Glycosphingolipids  
 Gene expression, human glycosyltransferase, 75  
 Gene silencing, 275  
 Genetic and metabolic engineering of insect cell glycosylation pathways, 349  
 Germ cells, primordial, 41, 42. *See also* Stem cells  
 GF. *See* Growth factors  
 GFAP. *See* Glial fibrillary acidic protein  
 Gg1b family, 287  
 Gg3, 125, 149  
 GLAST. *See* Glutamate transporter  
 GlcN. *See* Glucosamine  
 GlcNAc (*N*-acetylglucosamine), 3, 21, 31, 149. *See also* GalNAc (*N*-acetylgalactosamine)  
   GlcNAc2, 377  
   GlcNAc-1-P  
     (*N*-acetylglucosamine-1-phosphate), 343  
   GlcNAc-6-P  
     (*N*-acetylglucosamine-6-phosphate), 343  
   O-linked, 399(P1)  
   residues in tobacco N-glycans, 412(P40)  
   to Man $\alpha$ (1,3)-branch, 349  
   (GlcNAc-Man)2-Man-GlcNAc2, 377  
 Glial fibrillary acidic protein, 337  
 Gln(GlcNAc), 377  
 Globoid cell leukodystrophy, 299  
 GluC. *See* Glucosylceramide  
 Glucans, osmoregulated periplasmic, 401(P7)  
 Glucosamine, 149, 361, 413(P42)  
 Glucose, 149, 361  
 $\alpha$ -glucosidase  
   expression in transgenic rabbits, 408(P27)  
    $\alpha$ -glucosidase I, 347  
    $\alpha$ -glucosidase II, 347  
 Glucosyl phosphatidyl inositol, 461  
 Glucosylceramide, 97  
 Glutamate excitotoxicity, 305–312  
 Glutamate transporter, 337  
 Glutamine synthase, 337  
 Glycan  
   cell surface, 111, 503  
   chain, monoglucosylated analogues of, 257–264  
   embryoglycan, 41  
   functional analysis using RNAi, 64  
   glycosaminoglycan, 47, 53, 65  
   GPI-anchor, 32  
   high-mannose type, 31  
   mediated recognition, species-specificity of, 121  
   neuroglycan C, 53, 54  
   *N*-glycan, 35, 54, 394(O4)  
   *O*-glycan, 54, 394(O4)  
   on ICAM-3 recognized by C-type lectin DC-SIGN, 406(P23)  
   profiling, 35, 37  
   proteoglycan, 361  
     chondroitin sulfate, 53  
     d $\beta$ 4GalTI, 65–68  
     proteoglycan, 111  
     synthesis, 417(P56)  
 Glycan-glycan  
   adhesion, 117  
   recognition, 115  
 Glycobiology, 393(O1)  
   chip electrospray mass spectrometry in, 398(O17)  
 Glyco-catch method, 35  
 Glycoconjugate  
   and drug research, 427–428  
   arrays, 397(O15)  
   ions, ECD of, 411(P35)  
   LacdiNAc-containing, 415(P49)  
   models constructed from glycolipid monolayers and artificial glycoconjugate polymers, 139  
   neoglycoconjugate, 151, 251  
   organization involved in *trans*- and *cis*-CCI, 133

- polymers, 139  
 specific antibody-bound gold NanoWire arrays (GNWA), 487
- Glycoforms, 70
- Glycogene  
 $\beta$ 3-glycosyltransferase ( $\beta$ 3GT) motif, 19  
 $\beta$ 4-glycosyltransferase ( $\beta$ 4GT) motif, 18  
 Glycogene (GG) Project, 17–22  
 polypeptide *N*-acetylgalactosaminyltransferase, 20
- Glycolipid  
 complex calcium ions, 170  
 from *Schistosoma mansoni*, 410(P33)  
 micelles, 89  
 modifying  $\alpha$ ,4-7-*N*-acetylgalactosaminyltransferase, 411(P36)  
 monolayers, 139
- Glycomics  
 functional, 35  
 structural (SG), 35
- Glyconanoparticles, 149  
 gold, 155, 402(P11)  
 Le<sup>X</sup>GNPs, 156
- Glyconanotechnology  
 adhesion evaluation, 152  
 as tools in anti-adhesive therapy, 158–160  
 gold glyconanoparticles, 155  
 Le<sup>X</sup>-Le<sup>X</sup> interaction, 156  
 mediated CCI, 149  
 neoglycoconjugates, 151  
 studying and evaluating, 152
- Glycopeptide  
 anti-adhesion therapy and, 471  
 fragment ion analysis, 417(P54)  
 libraries by *Ricinus communis* agglutinin, 409(P31)  
 MUC1, 396(O11)  
 screening, 400(P4)  
 solid-phase synthesis of, 197–202
- Glycoprotein, 343. *See also* Glycoproteomics  
 artificial, 69, 70, 73  
 CD75s-bearing glycoproteins, 409(P32)  
 characterization by mass spectrometry, 399(O19)  
 fluorescent NeuAc-labeled surface, 453  
 genome-wide analysis of, 415(P50)  
 GPI anchored, 31  
 haemolymph, 395(O7)  
 integrins, 9–15  
 LAMP (lysosomal major glycoprotein), 44  
 Le<sup>X</sup>-carrying  
   basigin, 43  
   embigin, 43  
    $\alpha$ 6integrin, 43  
 myelin-associated, 97  
 myelin/oligodendrocyte, 97  
 N-glycan from, 279  
 N-linked, 479  
 O-mannosyl-modified, 3–6  
 profiling in *Arabidopsis*, 398(O18)  
 sialylation of, 353  
 transmembrane, 53
- Glycoprotein quality control, 257–264  
 high-mannose-type oligosaccharide  
   facile synthesis and partial structure of, 70  
   synthesis of, 69  
 synthetic oligosaccharides and proteins,  
   analysis of interaction between, 74
- Glycoproteomics  
 functional glycomics, 35  
 structural glycomics (SG)  
   databases, 38  
   fluorescence detection, 37  
   frontal affinity chromatography, 35  
   glycan profiling, 35, 37  
   hect-by-hect project, 37–38  
   of schistosomes, 394(O6)
- Glycosaminoglycan, 47, 53, 65, 329, 361.  
*See also* Sulfotransferases
- Glycoscreening and sequencing, 404(P15)
- Glycosidase, 243, 344, 408(P29)
- Glycoside, cluster, 227
- Glycosphingolipid, 125, 149  
 dependent adhesion, 128–130  
 enriched microdomains, 97  
 enriched signaling domains of, 100  
 metabolism and cell-fate decisions in cancer  
   and stem cells, 315–325
- Glycosphingolipid for botulinum neurotoxin,  
 287–291  
 binding of, 289, 291  
 function of, 291  
 interaction with, 290  
 progenitor toxin, binding by, 290
- Glycosphingolipid storage disease. *See also*  
 Lysosomal storage disease  
 apoptosis and inflammation, 299  
 biochemical pathways involved in neuronal cell  
   dysfunction and death, 300–302  
 clinical description of, 295  
 Fabry disease, 299  
 Gaucher disease, 296  
 globoid cell leukodystrophy, 299  
 GM1 gangliosidosis, 296  
 GM2 gangliosidosis, 296  
 Krabbe disease (Globoid cell  
   leukodystrophy), 299  
 metachromatic leukodystrophy, 299  
 Niemann-Pick disease A and B, 299  
 sphingolipid storage diseases, clinical  
   features of, 298–299  
 enzymatic defect, 296
- Glycosphingolipidoses, 295
- Glycosylation, 165, 251, 343, 347  
 asparagines-linked protein, 479  
 congenital defects of glycosylation, 394(O4)  
 CS (chondroitin sulfate), 54  
 in PKA deficient mutants, 479, 481  
 in viral antigens, 394(O5)
- NGC  
 N-glycosylation, 54  
 O-glycosylation, 54
- N-glycosylation  
 integrins, 9–13  
 NGC, 54  
 plant N-glycosylation, 275
- O-GlcNAc, 409(P30)
- O-glycosylation, 396(O11), 401(P6)  
 of  $\alpha$ -dystroglycan, 5  
 pathways, insect cell, 349  
 plant N-glycosylation, 275  
 role in DNA-binding, 409(P30)  
 TNF $\alpha$ -induced changes in, 404(P17)
- Glycosylphosphatidylinositol. *See* GPI
- Glycosyltransferase, 63, 275, 345. *See also*  
 Glycogene  
 $\beta$ 1, 3-galactosyltransferase, 267  
 $\beta$ 3GT ( $\beta$ 3-glycosyltransferase), 19  
 $\beta$ 4GT ( $\beta$ 4-glycosyltransferase), 18  
 based N-glycosylation, 9  
 based O-mannosylation, 3  
*Drosophila* orthologs of a human, 64  
 expression in microbial hosts, 413(P43)  
 functional analysis  
   in vitro, 21  
   in vivo, 21  
 GnT-III, 9  
 GnT-IX, 21  
 GnT-V, 9  
 immobilization of, 76  
 secretion, 25–28  
 using bioinformatics, 17–18
- Glycosyltransferase genes in yeast, 75  
 immobilization, 76  
 production of, 76
- Glycosynapse, 125  
 carbohydrate-to-carbohydrate interaction  
   through, 125  
 GSL signaling between membranes via, 99  
 in myelin, 97  
 role in OLS/myelin, 105
- Glycotherapeutics, 471. *See also* Anti-adhesion  
 therapy
- GM1  
 derivative, tritium-labeled, 461  
 ganglioside, 305–312  
 gangliosidosis, 296
- GM2 gangliosidosis, 296
- GM2/GD2 synthase-null mice, 305–312
- GM2-synthase knockout mice, 322–323
- GM3, 125, 149  
 lactose and, 89
- GM3-Gg3 interaction  
 Ca<sup>2+</sup> ions effect, 146  
 driving forces of, 145–146  
 SPR study of, 139, 142  
 using clustered glycoconjugate models, 139  
 $\pi$ -A isotherm, 142–143
- GM3-synthase knockout mice, 322–323
- GN2. *See* GlcNAc2
- GNA. *See* *Garanthas nivalis* agglutinin
- GNP. *See* Glyconanoparticles
- GnT, 76  
 IGnT, 21, 44  
 GnT I, 275, 276, 343, 347  
 GnT II, 275, 277, 343, 347  
 GnT-III, 9, 412(P40)  
 GnT-IX ( $\beta$ 1,6-*N*-acetylglucosaminyltransferase),  
 21  
 GnT-V, 9
- GNW. *See* Gold nanowire
- GNWA. *See* Gold nanowire array
- Gold glyconanoparticles, 155  
 carbohydrate mediated self-recognition of  
   marine sponge cells, 402(P11)

- Gold nanowire, 487. *See also* Nano-biosensor
- Golgi apparatus, 25
- Gonadotropin, <sup>15</sup>N-labeled human chorionic, 400(P5)
- gp28 from *Mucuna pruriens* Seeds, 403(P12)
- GPCR. *See* G protein-coupled receptor
- GPI (glycosylphosphatidylinositol), 76, 97  
anchored glycoprotein, 31  
recognition of TNF- $\alpha$ , 32  
anchored surface antigens, 400(P3)  
of *Plasmodium falciparum*, 413(P42)
- Granulomas, 415(P49)
- Growth factor, 47  
epidermal (EGF), 53, 125  
HBGF (heparin-binding growth factor), 49
- GS. *See* Glutamine synthase
- GSD. *See* Glycosphingolipid storage disease
- GSL signaling between membranes via glycosynapse, 99
- GSL. *See* Glycosphingolipid
- Guanidine hydrochloride, 361
- Guanosine-5'-diphosphofucose, 343
- Guanosine-5'-diphosphomannose, 343
- H
- H. pylori*, 251  
binding specificities of, 397(O15)
- HA. *See* Hemagglutinin
- Haemolymph glycoproteins, 395(O7)
- Halichondria* proteoglycan, 120
- hAP. *See* Human alkaline phosphatase
- HAS. *See* Human serum albumin
- HBGF. *See under* Heparin-binding growth factor
- hDS2ST, 50
- Heart transplantation effect on xylosyltransferase I activity, 414(P47)
- Hect-by-hect project, 37–38. *See also* Structural glycomics (SG)
- Helicobacter pylori*. *See H. pylori*
- Hemagglutinin, 287, 471
- Hematopoietic precursor cells, 451
- Hematopoietic stem cells, 41, 43
- Heparan sulfate, 330, 361  
fine structure of, 49  
HS2ST (heparan sulfate 2-*O*-sulfotransferase), 47, 50  
HS6ST (heparan sulfate 6-*O*-sulfotransferase), 47  
dHS6ST, 50  
zHS6ST, 49  
signaling, 47
- Heparin  
sulfate, 330  
binding growth factor (HBGF), 49
- Heparin-like oligosaccharides on polymer supports, synthesis of, 179–194
- Hepatic granuloma formation in schistosomiasis, in vivo model for, 415(P49)
- HEPES, 149
- Hexasaccharide synthesis, Lewis b, 251–255
- Hexosamine HexN), 361  
compositional analysis, 363
- HFA, 393(O2)
- HIC1, 409(P30)
- High-affinity inhibitors of type 1 fimbrial adherence of *E. coli*, 398(O16)
- High-mannose type glycan, 31
- High-mannose-type oligosaccharide  
synthesis of, 69  
synthetic analogues of, 72
- High-performance anion-exchange chromatography, 401(P8)
- High performance liquid chromatography, 275, 343, 461
- Histo-blood group P<sup>k</sup> gene, 411(P36)
- HL60 cells, adhesion and differentiation of, 407(P26)
- HNK-1  
antibody, 54  
CSPG, 332–333
- Homeostasis, Ca<sup>2+</sup>, 305–312
- Homology, XL-35  
human homologs of, 445–446  
mouse homologs of, 446, 448  
other organisms, 449
- Horseradish peroxidase, 361
- HPAEC. *See* High-performance anion-exchange chromatography
- HPC. *See* Hematopoietic precursor cells
- HPLC. *See* High performance liquid chromatography
- HRP. *See* Horseradish peroxidase
- HS. *See* Heparan sulfate
- HS2ST (heparan sulfate 2-*O*-sulfotransferase)  
*Drosophila* HS2ST, 50  
fine structure of, 49  
mHS2ST, 50  
substrate preferences and expression patterns of, 47–48
- HS6ST (heparan sulfate 6-*O*-sulfotransferase)  
dHS6ST (*Drosophila* HS6ST), 50  
fine structure of, 49  
substrate preferences and expression patterns of, 47–48  
zHS6ST (Zebrafish HS6ST), 49
- HSP70, 396(O10)
- hST8SiaVI, identification and enzymatic characterisation of, 415(P48)
- Human alkaline phosphatase (hAP), 31
- Human articular chondrocyte transplants, 412(P38)
- Human CD34 progenitors. *See* CD34 progenitors, from peripheral blood and bone marrow
- Human dermatan/chondroitin sulfate hexuronic acid-2-*O*-sulfotransferase (hDS2ST), 50
- Human endothelial cells, TNF $\alpha$ -induced changes in glycosylation of, 404(P17)
- Human glycosyltransferase genes in yeast, 75
- Human homologs of XL-35, 445–446
- Human serum albumin, 251
- Human serum albumin conjugation, 255
- Human umbilical cord blood vessels.  
*See* umbilical cord blood vessels, proteoglycan characterization of
- Human umbilical vein endothelial cells, 405(P18)
- Hyalectins, 329
- Hyaluronic acid, 361
- 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid. *See* HEPES
- $\alpha$ -hydroxyphosphonates, synthesis of, 221
- Hypomyelination in transgenic mice overexpressing polysialyltransferase STSSialV in oligodendrocytes, 403(P14)
- I
- ICAM-2, 405(P18)
- ICAM-3, 406(P23)
- ICP. *See* Inductively coupled plasma-atomic emission spectrometry
- IGnT ( $\beta$ -1, 6-*N*-acetylglucosaminyltransferases), 21, 44
- IKK, 430  
activity, 437  
assay, 432
- IL. *See* Interleukin
- IL-2. *See under* Interleukin
- Immobilization, glycosyltransferase genes in yeast, 75
- Immunity, 503, 512–513
- Immunoblot analysis, 277
- Immunofluorescence assay, 431
- Immunohistochemistry, 364
- Immunoprecipitation, 453
- In vitro* cell migration and ECM invasion.  
*See under* MMP-2
- In vivo  
model for hepatic granuloma formation in schistosomiasis, 415(P49)  
O-glycosylation, regulation of, 401(P6)  
tumor growth of MDA-MB-231 breast cancer cells, 408(P28)
- Inductively coupled plasma-atomic emission spectrometry, 149
- Inflammation, 393(O1)  
in GSD, 295, 299
- Influenza. *See also* Anti-adhesion therapy  
influenza A, 471  
influenza B, 471
- Inhibitors, sialyltransferase, 205–218, 221–225
- Insect cell, 343, 346  
fucosylation in, 348  
FucT C3 activity in, 354
- Insect cell glycosylation pathways, genetic and metabolic engineering of  
addition of Gal to Man $\alpha$ (1,3)-branch, 350  
CMP-NeuAc generation, 351  
elongation of Man $\alpha$ (1,6)-branch with GlcNAc and Gal, 351  
expression of sialyltransferase and sialylation of glycoproteins, 353  
FucT C3 activity in insect cells, 354  
GlcNAc to Man $\alpha$ (1,3)-branch, 349
- Insect cell processing, 346  
CMP-NeuAc synthesis pathways, 349  
fucosylation, 348  
galactosylation, 347  
sialylation, 348  
sugar nucleotides, 349  
 $\alpha$ -glucosidase I, 347  
 $\alpha$ -glucosidase II, 347  
 $\alpha$ -mannosidase I, 347  
 $\alpha$ -*N*-acetylglucosaminidase, 348
- Integrins, 9–15  
 $\alpha$ 6integrin, 43

- integrin $\alpha$ 3 $\beta$ 1  
 integrin $\alpha$ 5 $\beta$ 1  
 N-glycosylation effect on cross-talk between growth factor receptors and integrins-mediated signals, 12  
 N-glycosylation of, 11  
 structures of N-linked oligosaccharides, 10  
 sugar modeling modulated function of, 11  
 Interleukin  
   IL-2, 31  
   IL-2R (IL-2 receptor), 31  
 Intracellular Ca<sup>2+</sup>, 305–312  
 Ionic strength, 89  
 Ionization ion-trap mass spectrometry, 401(p8)  
 Isotherm,  $\pi$ -a, 139, 142, 143  
 Isothermal titration calorimetry, 149, 257, 263, 264  
 ITC. *See* Isothermal titration calorimetry  
 ITMS. *See* Ionization ion-trap mass spectrometry  
 I $\kappa$ B kinase. *See* IKK  
  
 K  
 K<sup>+</sup> channels, 59, 60  
 KCl induced apoptosis, 305  
 KDN, 343  
 KDNGM3, 149  
 Keratan sulfate, 330  
 2-keto-3-deoxy-D-glycero-D-galactonic acid.  
   *See* KDN  
 Ketones  
   TLCK, 361  
   TPCK, 361  
 Keyhole limpet hemocyanin, 405(P20)  
 Kidney. *See also* Nano-biosensor  
   infection, 487  
   L-selectin ligand in, 60  
 Kinase  
   cAMP-dependent, 479  
   I $\kappa$ B. *See* IKK  
 KK $\beta$ , 406(P22)  
 KLH. *See* Keyhole limpet hemocyanin  
 Knockout, 305–312  
 Knockout mice, polysialylation in, 393(O3)  
 KO. *See* Knockout  
 Krabbe disease (Globoid cell leukodystrophy), 299  
 KS. *See* Keratan sulfate  
  
 L  
 LacC14, 89  
 LacCer, 89. *See also* GalCer  
 LactiNAc-containing glycoconjugates, 415(P49)  
 LacNAc, 415(P49)  
 Lactosamine, 451  
 Lactose, 149  
 Lactose and GM<sub>3</sub>, CCI between, 89  
 Lactosyl ceramide, 89  
 LAMP (lysosomal major glycoprotein), 44  
 Langmuir monolayers, 89  
 LC-ESI-IT-MS, 399(O19)  
 Le<sup>a</sup>, 125  
 Lead compounds from O-, S- and N-linked glycopeptide libraries by *Ricinus communis* agglutinin, 409(P31)  
 Lectin, 35  
   C-type lectin, 395(O8), 406(P23)  
   lectin-chaperone calreticulin and calnexin, ligand of, 257–264  
   mannan-binding (MBL), 79  
   *Psathyrella velutina*, 31  
   staining, flow cytometric analysis of, 453  
   XL-35. *See* XL-35  
   X-lectins, 443  
 Lepidopteran insect cells, sugar nucleotides in, 349  
 Leukemia, acute myeloblastic, 452  
 Leukocyte, 393(O1)  
   polymorphonuclear, 79  
 Leukodystrophy  
   globoid cell, 299  
   metachromatic, 299, 403(P13)  
 Lewis antigens, 395(O8)  
 Lewis b hexasaccharide synthesis, 251–255  
 Lewis X (Le<sup>x</sup>), 125  
   antigen, 41  
   carrying glycoprotein  
     basigin, 43  
     embigin, 43  
      $\alpha$ 6integrin, 43  
   determinant, 111  
 Le<sup>x</sup>GNPs TEM, Self-aggregation studies of, 156  
 Le<sup>x</sup>-Le<sup>x</sup>  
   interaction by means of biosensors with SPR detection, 156  
   recognition with calcium ions, Lewis X determinant interactions, 170  
 Lewis<sup>x</sup> determinant interactions  
   materials and method  
     glycosphingolipids, 166  
     vesicle adhesion energy measurements, 166–168  
   quantified by lipid vesicle micromanipulation, 165  
   results  
     Le<sup>x</sup>-Le<sup>x</sup> recognition with calcium ions, 170  
     non-specific NaCl, 169  
 Le<sup>x</sup>, 125. *See* Lewis X (Le<sup>x</sup>)  
 Le<sup>y</sup>, 125, 130  
 Ligand  
   bound MBP, 79  
   of lectin-chaperone calreticulin and calnexin, 257–264  
 Ligands of asialoglycoprotein receptor for targeted gene delivery  
   binding studies with biotinylated cluster glycosides, 227  
   materials and methods, 235  
   flow cytometry analysis, 227, 240  
   liquid-phase synthesis, 238  
   solid-phase synthesis, 236, 238  
   synthesis of, 227  
   biotin-labelled GalNAc ligands, 228  
   solid-phase synthesis, 228, 230  
   solution phase chemistry, 230  
 Lipid  
   domains, 461  
   galactolipids, 98  
   glycolipid micelles, 89  
   glycolipid, 139  
   glycosphingolipid (GSL), 97, 125, 295, 315–325  
   for botulinum neurotoxin, 287–291  
   phospholipids, 295  
   rafts, 97  
   seminolipid, 59  
   sphingolipids, 295, 315–325, 465  
   sulfoglycolipids, 59  
   vesicle micromanipulation, 165  
 Lipid-linked oligosaccharide  
   asparagines-linked protein glycosylation, 479  
   Chinese hamster ovary cells expression, 479  
   Dol-P-Man synthase, functionally altered, 479  
   protein glycosylation in PKA deficient mutants, 479–483  
 Lipopolysaccharide, 487  
 Liposomes, GalC/SGC-containing, 102  
 Liquid column chromatography (LC), 31  
 Liquid-phase synthesis, 238. *See also* solid-phase synthesis  
 LLO. *See* Lipid-linked oligosaccharide  
 Lotus tetragonolobus agglutinin (LTA), 41  
 LPS. *See* Lipopolysaccharide  
 LSD. *See* Lysosomal storage disease  
 L-selectin ligand in kidney, 60  
 Lysosomal major glycoprotein (LAMP), 44  
 Lysosomal storage disease, 295. *See also* glycosphingolipid storage disease  
  
 M  
 M1GN2, 377  
 MAA. *See* *Maackia amurensis* agglutinin  
 Maackia amurensis agglutinin, 451  
 MAb. *See* Monoclonal antibody  
 MAG. *See* Myelin-associated glycoprotein  
 MALDI-TOF, 251, 275  
 MALDI-TOF MS, 377  
 MALDI-TOF/TOF-MS, 417(P54)  
 MaltC14, 89  
 Maltose, 149  
 Mammary carcinoma cells,  
   N-glycolylneuraminase biosynthesis in, 416(P53)  
 Man. *See* Mannose  
 Man-GlcNAc2, 377  
 Man3-GlcNAc2, 377  
 ManNAc, 343  
 ManNAc-6-P N-acetylmannosamine-6-phosphate, 343  
 Mannan-binding lectin (MBL), 79  
 Mannan-binding protein (MBP)  
   ligand-bound, 79  
   PMN aggregation by, 82  
   PMN stimulation by, 81  
   quantification of, 81  
   superoxide production from human polymorphonuclear leukocytes by, 79  
 $\alpha$ -mannosidase I, 347  
 $\alpha$ -mannosidase II, 347  
 Mannoproteins, 417(P55)  
 Mannosamine, 413(P42)  
 Mannose, 31, 343. *See also* High-mannose-type oligosaccharide  
   benzyl, 396(O12)  
   D-mannose, 377  
 $\alpha$ -mannosidase I, 347



- $\alpha$ -mannosidase II, 347  
 Mannosidase-like proteins (MLP), 69  
 Mannosylphosphodolichol synthase. *See* DPMS  
 Mannosylphosphodolichol, 479  
 MAPK. *See* Mitogen-activated protein kinase  
 MAPK/ERK kinase (MEK), 100  
 Marine sponge cells, 402(P11)  
 Markers, carbohydrate, 41  
 Mass spectrometry (MS), 31, 364, 410(P34), 417(P54)  
   for glycopeptide screening, 400(P4)  
   in structural glycobiology, 398(O17)  
   glycoproteins characterization by, 399(O19)  
   ITMS, 401(P8)  
   mannoproteins, 417(P55)  
 Matrix metalloproteinases. *See* MMP  
 Matrix-assisted laser desorption ionization-time of flight. *See* MALDI-TOF  
 Matrix-assisted laser desorption ionization time-of-flight mass spectrometry. *See* MALDI-TOF MS  
 MBL. *See* Mannan-binding lectin  
 MBP. *See* Myelin basic protein  
 MBP. *See* Mannan-binding protein  
 MCT (monocarboxylic acid transporters), 43  
 MDA-MB-231 breast cancer cells, in vivo tumor growth of, 408(P28)  
 ME ( $\beta$ -Mercaptoethanol), 487  
 MEB. *See* Muscle-eye-brain disease  
 MEK1, 13  
 Melanoma, 89  
 Membranes, 89  
 Membrane-bound sialomucin, 41  
 Membrane microdomain, 497-500  
 Membrane organization, CCI through glycosynapse as basis of, 125  
 $\beta$ -Mercaptoethanol, 487  
 MES, 275  
 Metabolic engineering, 343  
 Metabolism, glycosphingolipid, 315-325  
 Metachromatic leukodystrophy, 299, 403(P13)  
 Methotrexate (MTX), 71  
 Methylotrophic yeast, 76  
 MGDG. *See* Monogalactosyldiglyceride  
 mHS2ST, 50  
 Mice  
   CST-null, 59  
   expression, transgenic, 393(O2)  
   GD2-synthase knockout, 322-323  
   GM2/GD2 synthase-null mice, 305-312  
   GM2-synthase knockout, 322-323  
   GM3-synthase knockout, 322-323  
   transgenic rescue of UDP-galactose:ceramide galactosyltransferase deficient, 418(P57)  
 Micelles, glycolipid, 89  
*Microciconia* proteoglycan, 115, 120  
 Mitogen-activated protein kinase, 97  
 MLD. *See* Metachromatic leukodystrophy  
 MLP. *See* Mannosidase-like proteins  
 MMP, 429  
 MMP-2  
   ASMMP-2, 435  
   cell migration assay, 431  
   ECM invasion assay, 432  
   electrophoretic mobility shift assay, 432  
   IKK assay, 432  
   immunofluorescence assay, 431  
   *in vitro* cell migration and ECM invasion  
     curcumin role in, 435  
     MMP-2 role in, 435  
     OPN enhancing, 434  
   I $\kappa$ B $\alpha$  phosphorylation and IKK activity, 437  
   mechanism and regulation of NF- $\kappa$ B-mediated activation, 429  
   MMP-2 specific sense (SMMP-2), 435  
   MT1-MMP expression  
     by activating NF- $\kappa$ B, 433  
     curcumin blocking OPN-induced, 433  
     OPN induced, 433  
   NF- $\kappa$ B luciferase reporter gene assay, 432  
   nuclear and cytoplasmic fractionation and western blot, 431  
   propidium iodide (PI) staining of cells, 432  
   role in cell motility and ECM-invasion, 429  
   SMMP-2, 435  
   Western blot analysis, 431  
   zymography for MMP-2 activity detection, 430  
 MMP-2 specific sense (SMMP-2), 435  
 MOG. *See* Myelin/oligodendrocyte glycoprotein  
 Molecular analysis of transgenic plant, 278  
 Molecular characterization, tissue-engineered human articular chondrocyte transplants, 412(p38)  
 Monocarboxylic acid transporters, 43  
 Monoclonal antibodies, 115, 451, 394(O6) 4C9, 43  
   specificity against *Schistosoma mansoni* antigen, 402(P10)  
 $\alpha$ -(2,3)-monosialyl oligosaccharide, 248  
   Monogalactosyldiglyceride, 97  
 Monoglucosylated glycan chain, analogues of, 257-264  
 Monolayers  
   glycolipid, 139  
   Langmuir, 89  
   self-assembled, 487, 491, 493  
 Monosialyl decasaccharide,  $\beta$ -D-Galactosidase digestion of, 248, 249  
 Monosialyl nonasaccharide, N-acetyl- $\beta$ -D-glucosaminidase digestion of, 249  
 Monosialyl octasaccharide,  $\alpha$ -D-mannosidase digestion of, 249  
 $\alpha$ -(2,3)-monosialyl oligosaccharide, 248  
 Morphogen, 47  
 Mouse. *See also* Mice  
   ES and related cells in, 41  
   homologs of XL-35, 446, 448  
   model, neuronal phenotype of metachromatic leukodystrophy and, 403(P13)  
 mRNA, 55, 406(P22)  
 MS. *See* Mass spectrometry  
 MT1-MMP expression  
   by activating NF- $\kappa$ B, 433  
   curcumin blocking OPN-induced, 433  
 MTT, 305-312  
 MTX (methotrexate), 71  
 MUC1 glycopeptide, 396(O11)  
 Mucin, sialomucin, 41  
 Mucin type O-glycosylation, 405(P19)  
*Mucuna pruriens* Seeds, 403(P12)  
 Multimeric glycotherapeutics, 471  
 Multimeric paa conjugates, 472  
 Muscle-eye-brain disease, 5-6  
 Muscular dystrophy, congenital, 3-6. *See also* O-mannosyl glycans  
   Fukuyama-type congenital dystrophy (FCMD), 5, 6  
   muscle-eye-brain disease (MEB), 5-6  
   Walker-Warburg syndrome (WWS), 5-6  
 Mutant enzymes, 395(O9)  
 Myelin, 59, 393(O2)  
   associated glycoprotein, 97  
   galactolipids importance in, 98  
   glycosynapse in, 97  
   MBP (myelin basic protein), 97, 337  
   Myelin/oligodendrocyte glycoprotein, 97  
   Myelin basic protein, 97, 337  
 N  
<sup>15</sup>N-labeled human chorionic gonadotropin, 400(P5)  
*N. benthamiana*. *See* N-glycan profiles in *Nicotiana benthamiana*  
 N, N-dimethylformamide, 461  
 Na<sup>+</sup> channels, 59, 60  
 Na<sup>+</sup>/Ca<sup>2+</sup> exchanger, 305-312  
 N-acetyl- $\beta$ -D-glucosaminidase digestion of monosialyl nonasaccharide, 249  
 N-acetyl-calcitonin calcitonin receptor (CT-R), 377  
 N-acetyl-D-glucosamine, 377  
 N-acetyl-D-glucosaminyl-L-glutamine, 377  
 N-acetyl-D-neuraminic acid, 377  
 N-acetylgalactosamine. *See* GalNAc (N-acetylgalactosamine)  
 $\alpha$ ,4-7-N-acetylgalactosaminyl-transferase, glycolipid-modifying, 411(P36)  
 N-acetylglucosamine. *See* GlcNAc (N-acetylglucosamine)  
 $\alpha$ -N-acetylglucosaminidase, 348  
 N-acetylglucosaminyltransferase. *See* GnT  
 $\beta$ 1,3-N-acetylglucosaminyltransferase, 267  
 $\beta$ 1,6-N-acetylglucosaminyltransferase, 21, 44  
 N-acetylglucosaminyltransferase I. *See* GnT I  
 N-acetylglucosaminyltransferase II. *See* GnT II  
 N-acetylglucosaminyltransferase III. *See* GnT-III  
 N-acetylglucosaminyltransferase V. *See* GnT-V  
 N-acetylmannosamine, 343  
 N-acetylneuraminic acid, 343  
 N-acetylneuraminic acid-9-phosphate, 343  
 N-acyl side chain of sialic acid, biochemical engineering of, 407(P26)  
 N-acyl-sphingosine, 461  
 Nano-biosensor  
   antibodies  
     attachment to electrode surface, 491  
     binding to gold patterns, 490  
     immobilization, 491  
     removal from GNW, 491  
   antibody-bound gold nanowire arrays, use of, 487  
   DSU synthesis, 490  
   DSU-SAM binding, 493  
   EIS detection, 491, 494, 495  
   electrode surface fabrication, 489

- for bacterial detection during human kidney infection, 487
- Nano LC-ion trap mass spectrometry, 417(P54)
- NanoESI, 398(O17)
- Nanomelia, 329
- Nanowire array, 487. *See also* nano-biosensor
- Nanowire, gold, 487. *See also* nano-biosensor
- NBT (nitroblue tetrazolium), 81
- NCAM. *See* Neural cell adhesion molecule
- NCX. *See* Na<sup>+</sup>/Ca<sup>2+</sup> exchanger
- NDVN. *See* Newcastle disease virus neuraminidase
- NE. *See* Nuclear envelop
- Neisseria meningitidis*  $\alpha$ -2,3-sialyltransferase, 248
- NEM. *See* N-ethylmaleimide
- Neoglycoconjugate, 151, 251  
related to CAA antigen, 402(P10)
- N-ethylmaleimide, 361
- NeuAc, 343, 377
- NeuAc-9-P, 343
- Neural cell adhesion molecule, 97, 393(O3)  
polysialylation during postnatal brain development of mouse, 404(P16)
- Neural stem cells, 41, 42
- Neuraminic acid, 343
- Neuraminidase treatment, 379
- Neuritogenesis, 53  
NGC involvement in, 55
- Neurofascin-155 kDa, 97
- Neuroglycan C, 53  
cDNA, 55  
expression  
changes elicited by drug addiction and nerve injury, 55  
tissue specific, 55  
gene and splice variants  
NGC-I, 54, 56  
NGC-II, 54  
NGC-III, 54, 56  
glycosylation  
N-glycosylation, 54  
O-glycosylation, 54  
molecules interaction, 55  
mRNA, 55  
neuritogenesis involvement, 55  
phosphorylation, 54
- Neuronal cells, 461
- Neuronal plasma membranes, 461
- Neurons, cerebellar granule, 305-312
- Neurotoxin  
binding to gangliosides, 288-291  
botulinum, 287, 289
- Newcastle disease virus neuraminidase, 451
- Nf-155. *See* Neurofascin-155 kDa
- NFA, 393(O2)
- NF- $\kappa$ B, 429  
luciferase reporter gene assay, 432
- NGC. *See* Neuroglycan C
- N-glycan, 3, 35, 54, 394(O4), 397(O13). *See also* O-glycan  
from glycoprotein, 279  
mediated glycoprotein quality control, 257-264  
of recombinant human acid  $\alpha$ -glucosidase expressed in milk of transgenic rabbits, 408(P27)  
present on gp28 from *Mucuna pruriens* Seeds, 403(P12)  
tobacco, 412(P40)
- N-glycan processing in mammalian cell lines  
genetic and metabolic engineering of insect cell glycosylation pathways  
addition of Gal to Man $\alpha$ (1,3)-branch, 350  
CMP-NeuAc generation, 351  
elongation of Man $\alpha$ (1,6)-branch with GlcNAc and Gal, 351  
expression of sialyltransferase and sialylation of glycoproteins, 353  
FucT C3 activity in insect cells, 354  
GlcNAc to Man $\alpha$ (1,3)-branch, 349
- insect cell processing, 346  
CMP-NeuAc synthesis pathways, 349  
fucosylation, 348  
galactosylation, 347  
sialylation, 348  
sugar nucleotides, 349  
 $\alpha$ -glucosidase I, 347  
 $\alpha$ -glucosidase II, 347  
 $\alpha$ -mannosidase I, 347  
 $\alpha$ -N-acetylglucosaminidase, 348
- native and engineered lepidopteran insect cell lines, 343
- processing and maturation  
synthesis of complex-type N-glycans in the later steps by glycosyltransferases, 345  
trimming of N-glycans in the early steps by processing glycosidases, 344
- N-glycan profiles in *Nicotiana benthamiana*  
immunoblot analysis, 277  
molecular analysis of, 278  
transgenic plant generation, 276, 278  
 $\beta$ 1,2-N-acetylglucosaminyltransferase I activity, 275, 276, 278  
 $\beta$ 1,2-N-acetylglucosaminyltransferase II activity, 275, 277
- N-glycolylneuraminase biosynthesis in human mammary carcinoma cells, 416(P53)
- N-glycosylation, 9, 54. *See also* O-mannosylation  
defects in, 407(P25)  
eel calcitonin derivatives. *See* calcitonin derivatives, artificially N-glycosylated  
effect on cross-talk between growth factor receptors and integrins-mediated signals, 12  
in Edg-1/S1P1, 497-500  
of integrins, 9-13  
plant, 275
- Nicotiana benthamiana*, N-glycan profiles in. *See* N-glycan profiles in *Nicotiana benthamiana*
- Niemann-Pick disease A and B, 299
- Nitroblue tetrazolium (NBT), 81
- N-linked glycoprotein, 479  
libraries by *Ricinus communis* agglutinin, 409(P31)
- 2-(N-morpholino)ethanesulfonic acid, 275
- NMR. *See* Nuclear magnetic resonance
- Nonasaccharide, monosialyl, 249
- Northern blot analysis, *B3GALT7* gene, 267, 268
- N-propionylglucosamine, 397(O14)
- NST. *See* Nucleotide sugar transporters
- N-tetradecyl-O-cellobiosylglycolamide, 89
- N-tetradecyl-O-lactosylglycolamide, 89
- N-tetradecyl-O-maltosylglycolamide, 89
- N-tosyl-L-lysine chloromethyl ketone, 361
- N-tosyl-L-phenylalanine chloromethyl ketone, 361
- NTX. *See* Neurotoxin
- Nuclear and cytoplasmic fractionation and western blot, 431
- Nuclear calcium, 305-312
- Nuclear envelop, 305-312
- Nuclear magnetic resonance, 149, 377
- Nucleotide sugar transporters, 399(P2)
- O
- O-acetylated GalNAc, 228
- Octasaccharide, monosialyl, 249
- Ogatae minuta, 76
- O-GlcNAc, 399(P1)  
glycosylation of tumor suppressor, 409(P30)
- O-glycans, 3, 54, 394(O4). *See also* N-glycans  
analysis, for congenital defects in mucin type O-glycosylation, 405(P19)
- O-glycosylation, 54, 396(O11)  
mucin type, 405(P19)  
regulation of in vivo, 401(P6)
- OL. *See* Oligodendrocyte
- Oligodendrocyte, 97  
differentiation, 59  
galactolipids role in, 98  
GalC/SGC in, 100  
OLs/myelin  
glycosynapse role in, 105  
GSL-enriched signaling domains of, 100
- Oligomannoside binding by *Pterocarpus angolensis*, 402(P9)
- Oligosaccharides, 471  
asparagine linked, 243  
CHPAEC-PAD analysis, 401(P8)  
complex-type  
asialo biantennary, 377  
disialo biantennary, 377, 378  
ER high-mannose-type  
facile synthesis and partial structure of, 70  
synthesis of, 69  
fluorine substituted, 257-264  
heparin-like, 179-194  
high-mannose-type, 69  
lipid-linked, 479  
structural analysis of permethylated, 410(P34)  
synthesis of human type, 75  
synthetic, 74
- O-linked glycopeptide libraries by *Ricinus communis* agglutinin, 409(P31)
- O-linked N-acetylglucosamine, 396(O10), 399(P1)
- O-mannosyl glycans, 3  
biosynthesis, 4  
pathology  
Fukuyama-type congenital dystrophy (FCMD), 5-6  
muscle-eye-brain disease (MEB), 5-6  
Walker-Warburg syndrome (WWS), 5-6

- structure and occurrence, 3–4
- O*-mannosylation, 3. *See also* N-glycosylation
- O*-N-acetylglucosaminylation in protozoan parasite *Toxoplasma gondii*, 411(P37)
- OPN, 429. *See also* MMP-2
- OPN enhancing *in vitro* cell migration and ECM invasion, 434
- OPN induced MT1-MMP expression
- by activating NF- $\kappa$ B, 433
  - by activating NF- $\kappa$ B, 433
  - curcumin blocking OPN-induced expression, 433
  - curcumin blocking OPN-induced expression, 433
- OPN-induced I $\kappa$ B $\alpha$  phosphorylation and IKK activity, curcumin inhibiting, 437
- OPN-induced NF- $\kappa$ B activation, 436
- OPN stimulating I $\kappa$ B $\alpha$  phosphorylation via IKK activity, 437
- OPN treated cells, curcumin inducing apoptotic morphology in, 438
- Osmoregulated periplasmic glucans on *Erwinia chrysanthemi* proteome, 401(P7)
- Osteopontin. *See* OPN
- P
- PA. *See* Pyridylamino
- PAA. *See* Polyacrylamide
- PAD. *See* Pulsed amperometric detection
- PAF. *See* Platelet activation factor
- PAGE. *See* Polyacrylamide gel electrophoresis
- Paneth cells, 443
- PAPS transporter, 63, 64
- PAR. *See* Prostate apoptosis response
- Pathogens, 443
- PBPC. *See* Peripheral blood precursor cells
- PBS. *See* Phosphate buffered saline
- PC. *See* Phosphatidylcholine
- PCR, 75, 268, 275
- PE. *See* Phosphatidylethanolamine
- Peanut agglutinin, 451
- Peptide-N-acetylgalactosaminyltransferases (ppGalNAcT), 76
- Peripheral blood precursor cells, 451. *See also* CD34 progenitors, from peripheral blood and bone marrow
- PG. *See* Proteoglycans
- Phenylmethylsulfonyl fluoride, 361
- Phosphate buffered saline, 305–312, 361, 479
- Phosphatidylcholine, 97
- Phosphatidylethanolamine, 97
- Phosphatidylinositol specific phospholipase C (PI-PLC), 31
- Phosphatidylinositol-4,5-bisphosphate, 97
- Phosphatidylserine, 97
- Phospholipids, 295
- Phosphonates, 221–225
- Phosphorylation
- of 14-3-3 $\beta$  complexed with TTP, 406(p22)
  - NGC, 54
  - regulation, Dol-P-Man synthase, 479
- Photoactivable group linked to oligosaccharide chain, tritium-labeled GM1 derivative containing a photoactivable group linked to oligosaccharide chain, 461
- Photolabeling, 461
- Physiological saline solution, 305–312
- PI. *See* Propidium iodide
- Pichia pastoris*, expression of, 400(P5)
- Piconewtons, 111
- PIP2. *See* Phosphatidylinositol-4,5-bisphosphate
- Pipe* cDNA, 50. *See also* *Drosophila* HS2ST
- PI-PLC (phosphatidylinositol specific phospholipase C), 31
- Pir protein, 75
- PIST, 56
- P<sup>k</sup> gene, 411(P36)
- PKA, 479. *See also* cAMP-dependent protein kinase
- PKA deficient mutants
- 2-deoxy-D glucose, transport of, 483
  - LLO synthesis, rate of, 481
  - protein glycosylation in, 479, 481
- PKC $\delta$ , 406(P22)
- Plant N-glycosylation, 275
- Plasma membrane, 305–312
- neuronal, 461
- Plasmid expression, 268. *See also* B3GALT7 gene
- Plasmodium falciparum*, glycosylphosphatidylinositols of, 413(P42)
- Platelet activation factor, 79
- PLP. *See* Proteolipid protein
- PM. *See* Plasma membrane
- PMN suspension, 81, 82
- PMN. *See* Polymorphonuclear leukocytes
- PMSF. *See* Phenylmethylsulfonyl fluoride
- pN. *See* Piconewtons
- PNA. *See* Peanut agglutinin
- p*-nitrophenylphenol-phosphate, 487
- PNP (4-nitrophenyl), 149
- PNPP. *See* *p*-nitrophenylphenol-phosphate
- Polyacrylamide, 471
- Polyacrylamide gel electrophoresis, 275, 361, 479
- Polymer supports, heparin-like oligosaccharides on, 179–194
- Polymorphonuclear leukocytes, 79
- Poly-N-acetylglucosamines, 41
- Polypeptide N-acetylgalactosaminyltransferase, 20
- Polysaccharides, anti-corrosive, 416(P51)
- Polysialylation
- in ST8SiaII and ST8SiaIV knockout mice, 393(O3)
  - NCAM, 404(P16)
- Polysialyltransferase ST8SiaV in oligodendrocytes, 403(P14)
- Polystyrene, glycoconjugate, 139
- Polyvinylidene difluoride, 361
- Polyvinylmannose, 79
- POMGnT1, 4, 5
- POMT1, 78
- POMT2, 78
- Post natal brain development
- knockout mice, 393(O3)
  - of mouse, 404(P16)
- pp-GalNAc-T (polypeptide N-acetylgalactosaminyltransferase), 20
- PPI. *See* Protein-to-protein interaction
- Precursor cells
- hematopoietic, 451
  - peripheral blood, 451
- Primordial germ cells, 41, 42
- Profiling, glycan, 35, 37
- Progenitor toxin, 287, 288, 290
- Propidium iodide, 305–312
- Propidium iodide (PI) staining of cells, 432
- Prostate apoptosis response, 315–325
- Proteases in glycosyltransferase secretion, 25
- Protein glycosylation in PKA deficient mutants, 479, 481
- Protein *O*-mannose  $\beta$ 1,2-*N*-acetylglucosaminyltransferase. *See* POMGnT1
- Protein quality control system, 69
- Proteins, *O*-Mannosylation of, 3
- Protein-to-protein interaction, 125. *See also* Carbohydrate-to-carbohydrate interaction
- Proteoglycan, 53
- cell surface, 111
  - characterization of human umbilical cord blood vessels. *See* umbilical cord blood vessels, proteoglycan characterization of chondroitin sulfate, 329, 361
  - Cliona*, 120
  - d $\beta$ 4GalTI, 65–68
  - dermatan sulfate (DSPG), 361
  - Halichondria*, 120
  - in brain development
  - Microciona*, 115, 120
  - sponge, 112, 113
  - synthesis, 417(P56)
- Proteolipid protein, 97, 337, 393(O2)
- protozoan parasite *Toxoplasma gondii*, 411(P37)
- PS. *See* Phosphatidylserine
- Psathyrella velutina lectin, 31
- PSS. *See* Physiological saline solution
- Pterocarpus angolensis*, oligomannoside binding by, 402(P9)
- Pt-pincer, 407(P24)
- Pulsed amperometric detection, 401(P8)
- Purification methods, for sialyltransferase inhibitors synthesis, 211
- Pertussis toxin, 79
- PVDF. *See* Polyvinylidene difluoride
- PVL. *See* Psathyrella velutina lectin
- PV-Man, 80, 81
- Pyridylamino, 344
- Q
- Q38 form of ST6Gal I ( $\alpha$ 2,6-sialyltransferase), 26
- QCM. *See* Quartz crystal microbalance
- Quartz crystal microbalance (QCM), 90
- R
- Rabbits,  $\alpha$ -glucosidase expression in transgenic, 408(P27)
- Receptor internalization, 497–500
- Recombinant B3GALT7 gene. *See* B3GALT7 gene
- Recombinant DNA biotechnology, 343
- Retinal ganglion cells (RGC), 55
- Reverse transcriptase (RT), 275
- Reverse-transcription and polymerase chain reaction, 268
- Ricinus communis* agglutinin, glycopeptide libraries by, 409(P31)

- RISC (RNA-induced silencing complex), 64  
 RNA interference, 63  
   dsRNA, 64  
   knockdown of  $\delta\beta 4$ GalTI and dsII, dPAPS transporter, 65–68  
   knockdown system in *Drosophila*, 64  
 RNA isolation and reverse-transcription and polymerase chain reaction (RT-PCR), 268  
 RNAi. *See* RNA interference  
 RNA-induced silencing complex (RISC), 64  
 RT (reverse transcriptase), 275  
 RT-PCR, 268  
 rViscumin, 409(P32)
- S
- S. cerevisiae*. *See* *Saccharomyces cerevisiae*  
 S103L-CSPG gene, 332  
 SA. *See* Sialic acid  
*Saccharomyces cerevisiae*, 4, 76, 413(P44)  
   apoptosis in, 407(P25)  
   skeletal glycan layer in, 417(P55)  
*Sambucus nigra* agglutinin, 451  
 SAMs. *See* Self-assembled monolayers  
 SBA. *See* Soy bean agglutinin  
*Schistosoma mansoni*, 395(O8), 405(P20)  
   Biomphalaria glabrata with, 395(O7)  
 Schistosomiasis, 394(O6), 395(O7)  
   hepatic granuloma formation in, 415(P49)  
 Schizosaccharomyces pombe, 76  
*Sd* cDNA, 50. *See also* *Drosophila* HS2ST  
 SDS. *See* Sodium dodecyl sulfate  
 SDS-PAGE, 363, 480  
 Seawater  
   artificial, 111  
   calcium-and magnesium-free Tris-buffered, 111  
 $\beta$ -secretase. *See* BACE1  
 Secretion, glycosialyltransferase, 25  
 Self-aggregation studies of Le<sup>X</sup>GNPs by TEM, 156  
 Self-assembled molecules, 473  
 Self-assembled monolayers, 149, 487, 491, 493  
 Self-assembly, 471  
 Self-recognition of marine sponge cells,  
   carbohydrate mediated, 402(P11)  
 Self-renewal, 315–325  
 Seminolipid, 59  
   in spermatogenesis, 60  
 Serine (Ser), 3  
 Serum albumin. *See* Human serum albumin  
 SG. *See* Structural glycomics  
 SGC (sulfated galactosylceramide), 97  
 SGC and GalC  
   act as ligands, 99  
   trans interactions between, 101  
 SGP. *See* Sialyl glyco-hexapeptide derived from hen egg yolk  
 Sialic acid, 407(P26), 451, 471  
 Sialomucin. *See also* Carbohydrate antigens  
   CD164 (MGC-24v), 41, 43  
   membrane-bound (CD34), 41, 43  
 Sialyl glyco-hexapeptide derived from hen egg yolk, 377  
 Sialyl(N-acetyl)lactosamine. *See* SLN  
 Sialylation, 348  
   CD34 cell surface, 451  
   glycoproteins, 353  
 Sialyllactose, 471  
 $\alpha$ -(2,3)-sialyloligosaccharides  
   asparagine-linked, 243  
   *Neisseria meningitidis*, 248  
   rat recombinant, 248  
 Sialyloligosaccharides, asparagine linked  
   chemoenzymatic synthesis of, 243  
    $\alpha$ -(2,3)-disialyl oligosaccharide, 248  
   monosialyl deca-saccharide, 249  
   monosialyl nonasaccharide, 249  
   monosialyl octasaccharide, 249  
    $\alpha$ -(2,3)-monosialyl oligosaccharide, 248  
 Sialyl-Tn expression, breast cancer cells and, 408(P28)  
 Sialyltransferase, 76, 78, 344  
    $\alpha 2,6$ -sialyltransferase, 451  
   acceptor activities, 397(O14)  
   asparagine-linked  
      $\alpha$ -(2,3)-sialyloligosaccharides, 243  
   expression of, 353  
   *Neisseria meningitidis*  $\alpha$ -2,3-sialyltransferase, 248  
   rat recombinant  $\alpha$ -(2,3)-sialyloligosaccharides, 248  
   ST6GalII, 451  
 Sialyltransferase inhibitors, 205–218, 221–225  
   biological activity, 207  
   materials and method  
     analytical methods, 211  
     purification methods, 211  
   starting materials and reagents, 210  
   synthesis, 206–207  
     asymmetric synthesis of, 208–210  
     racemic synthesis of, 212  
 SiaT. *See* Sialyltransferase  
 Signal transduction, concurrent, 133  
 Signal transmission from GalC/SGC,  
   transmembrane, 101  
 Signaling, 97  
   GSL, 99  
   GSL-enriched signaling domains of, 100  
 Signaling systems  
   GF (growth factors), 47  
   heparan sulfate, 47  
   morphogen, 47  
 Skeletal glycan layer in *Saccharomyces cerevisiae*  
   cell wall, 417(P55)  
 SL. *See* Sialyllactose  
 S-linked glycopeptide libraries by *Ricinus communis* agglutinin, 409(P31)  
 SLN, 471  
 SM. *See* Sphingomyelin  
 Small intestine, 443  
 SMMP-2, 435  
 SNA. *See* *Sambucus nigra* agglutinin  
 SNAP-25, 287  
 Sodium dodecyl sulfate, 275  
 Solid-phase synthesis, 179–194. *See also*  
   liquid-phase synthesis  
   ligands of asialoglycoprotein receptor, 228, 230  
   of epidermal growth factor-like domain, 197–202  
 Solution phase chemistry, 230. *See also*  
   Liquid-phase synthesis; Solid-phase synthesis  
 Soy bean agglutinin, 451  
 Species-specific adhesion, 117  
 Species-specific aggregation, 115, 117  
 Species-specific carbohydrate composition,  
   proteoglycan molecules, 118  
 Species-specificity, 111  
   of glycan-mediated recognition, 121  
 Specific proteoglycan-mediated cell adhesion, 120  
 Specific proteoglycan-mediated cell recognition, 120  
 Specificity  
   feature of CCI, 131  
   of monoclonal antibodies against *Schistosoma mansoni* antigen, 402(P10)  
   sialyltransferase acceptor, 397(O14)  
 Spermatogenesis, 59  
 Sphingolipids, 295, 315–325, 465  
 Sphingolipid storage diseases, clinical features of, 298–299  
 Sphingomyelin, 97  
 Sphingosine, 461  
 Sphingosine 1-phosphate, 497–500  
 SPM. *See* Surface plasmon resonance  
 Sponge cells, 402(P11)  
 Sponge proteoglycans, EDTA-treatment of, 113  
 SPR screening, 407(P24)  
 SSEA, 41, 125, 149. *See also* Antigens  
 SSEA-1 expression, 41, 42  
 SSEA-3 expression, 41, 42  
 SSEA-4 expression, 41, 42  
 ST3Gal III, 397(O14)  
 ST6Gal I ( $\alpha 2,6$ -sialyltransferase)  
   alanine substitution effect on secretion, 27  
   cleavage by BACE1 protease, 25  
   Q38 form of, 26  
   cretion, 25  
 ST6GalII, 451  
 ST8SiaII and ST8SiaIV knockout mice,  
   polysialylation in, 393(O3)  
 ST8SiaV in oligodendrocytes, 403(P14)  
 Stage-specific embryonic antigen. *See* SSEA  
 Stem cells, 322. *See also* Carbohydrate antigens  
   carbohydrate antigens expression on, 41  
   embryonic, 41  
   glycosphingolipid metabolism in, 315–325  
   hematopoietic, 41, 43  
   neural, 41, 42  
   tumor, 323  
 Stereoselective synthesis, 205–218  
 STF. *See* Disialo biantennary complex-type oligosaccharide  
 Structural analysis of anti-corrosive polysaccharides, 416(P51)  
 Structural characterization of N-glycans present on gp28 from *Mucuna pruriens* Seeds, 403(P12)  
 Structural glycobiology, chip electrospray mass spectrometry in, 398(O17)  
 Structural glycomics (SG)  
   databases, 38  
   fluorescence detection, 37  
   frontal affinity chromatography, 35  
   glycan profiling, 35, 37

- hect-by-hect project, 37–38  
 Suberic acid, 251  
 Sucrose Synthase 1, biocatalytic properties of recombinant, 413(P44)  
 Sugar chain, enzymatic synthesis of, 75  
 Sugar nucleotide in lepidopteran insect cells, 349  
 Sugar-nucleotide transporter, 17–22, 63  
 Sulfated galactosylceramide. *See* SGC  
 Sulfatide, 97  
   endogenous L-selectin ligand in kidney, 60  
   in myelin function and oligodendrocyte differentiation, 59  
   storage in neurons of arylsulfatase A deficient mice, 403(P13)  
 Sulfation pattern in glycosaminoglycan, 47  
 Sulfoglycolipids biosynthesis, 58  
 Sulfotransferase, 17–22  
   cerebroside sulfotransferase (CST), 59  
   galactosylceramide 3'-sulfotransferase, 97  
   HS2ST (heparan sulfate 2-O-sulfotransferase), 47  
   HS6ST (heparan sulfate 6-O-sulfotransferase), 47  
 Superoxide production from human polymorphonuclear leukocytes  
   by PMN suspension, 81  
   materials and method, 79  
 Surface plasmon resonance, 90, 125, 139, 142, 149, 156, 287  
 Surface sialylation, 451  
 Synthesis design, 179–194  
 Synthesis, solid-phase, 197–202  
 Synthetic oligosaccharides and proteins, analysis of interaction between, 74
- T**
- T. gondii*. *See* *Toxoplasma gondii*  
 TAG-1, 461  
 Targeted gene delivery, 227  
 TBLASTN search of *Drosophila*, 64, 65  
 TCV-309, 79  
 TEM. *See* Transmission electron microscopy  
 TERA-2 cells, 129  
 Teratocarcinoma  
   human, 129  
   mouse, 126, 127  
 Tetraspanin, 125  
 TFA. *See* Trifluoroacetic acid  
 TFE. *See* Trifluoroethanol  
 Thin layer chromatography, 461  
 Thin polymer chip coupled to fourier transform ion cyclotron resonance mass spectrometry for glycopeptide screening, 400(P4)  
 Threonine (Thr), 3  
 TIMP. *See* Tissue inhibitors of matrix metalloproteases, 429  
 Tissue distribution, 361  
   B3GALT7 gene, 271  
   of human umbilical cord blood vessels, 370–371  
 Tissue-engineered human articular chondrocyte transplants, 412(P38)  
 Tissue inhibitors of matrix metalloproteases, 429. *See also* MMP-2
- Titration calorimetry and conformational modelling of oligomannoside binding by *Pterocarpus angolensis* Seed lectin, 402(P9)  
 TLC. *See* Thin layer chromatography  
 TLCK, 361  
 TNF. *See* Tumor necrosis factor  
 TNF $\alpha$  modulate  $\beta$ 1,4-galactosyltransferase I mRNA stability, 406(P22)  
 TNF $\alpha$ -induced changes in glycosylation of human endothelial cells, 404(P17)  
 TNFR (TNF $\alpha$  receptor), 31  
 Tobacco N-glycans, 412(P40)  
 Toxin  
   botulinum neurotoxin, 287  
   progenitor, 287, 288  
*Toxoplasma gondii*, 411(P37)  
*Toxoplasma gondii* glycosylphosphatidylinositols precursors, differential transfer of, 400(P3)  
 TPCK, 361  
 TRA-1-60 expression, 42  
 TRA-1-81 expression, 42  
 Trans-CCI based cell adhesion, 126–130. *See also*  
   Cis-CCI based cell adhesion  
   GSL-dependent adhesion, 128–130  
   homotypic cell adhesion through, 126  
   mouse embryo compaction, 127  
 Trans interaction, 125  
   between GalC and SGC, 101  
 Trans recognition, 44  
 Transcription termination region, 275  
 Transgenic mice  
   expression, 393(O2)  
   hypomyelination in, 403(P14)  
 Transgenic plant generation, 275, 278  
 Transgenic rabbits, N-glycans of recombinant human acid  $\alpha$ -glucosidase expressed in milk of, 408(P27)  
 Transgenic rescue of UDP-galactose:ceramide galactosyltransferase deficient mice, 418(P57)  
 Transglycosylation of disialo biantennary complex-type oligosaccharide, 378  
 Transition-state analogues, 205–218, 221–225  
 Transmembrane glycoproteins, 53  
 Transmembrane signal transmission from GalC/SGC, 101  
 Transmission electron microscopy, 149, 156  
 Trifluoroacetic acid, 111, 377  
 Trifluoroethanol, 377  
 TrkA, 12  
 TSP. *See* Tetraspanin  
 TTP, 406(P22)  
 TTR. *See* Transcription termination region  
 Tumor-associated CD75s-gangliosides and CD75s-bearing glycoproteins, 409(P32)  
 Tumor cell line, 267  
 Tumor growth of MDA-MB-231 breast cancer cells, in vivo, 408(P28)  
 Tumor necrosis factor  
   TNFR (TNF receptor), 31  
 TNF- $\alpha$ , 31  
 Tumor stem cells, 323  
 Tumor suppressor, O-GlcNAc glycosylation, 409(P30)
- U**
- U937 cell apoptosis, 32  
 UAS-inverted repeat (UAS-IR), 64  
 UDP-Gal, 97, 344  
 UDP-Galactopyranose Mutase in *Aspergillus fumigatus*, 414(P45)  
 UDP-galactose. *See* UDP-Gal  
 UDP-galactose:ceramide galactosyl transferase, 393(O2), 403(P13), 418(P57)  
 UDP-GalNAc, 344  
 UDP-GlcNAc, 344, 399(P2)  
 UDP-glucose:glycoprotein glucosyltransferase (UGGT), 69  
 UDP-Xylose synthase, Chinese Hamster Ovary cell deficient in, 417(P56)  
 UDP-Xylose, expression and purification of, 399(P2)  
 Ultraviolet-visible. *See* UV-vis  
 Umbilical cord blood vessels, proteoglycan characterization of  
   chondroitin sulfate, 361  
   compositional analysis  
     GAG chain disaccharide, 364  
     hexosamine, 363  
   core proteins  
     characterization, 368  
     identification by mass spectrometry, 364  
     NH<sub>2</sub> terminal sequencing of, 364  
   dermatan sulfate, 361  
   enzyme-linked immunosorbent assay, 364  
   GAG chains  
     characterization of, 366  
     disaccharide compositional analysis, 364  
     release of, 363  
     hexosamine compositional analysis, 363  
   immunohistochemistry, 364  
   PG isolation, 362  
   PG purification  
     Cesium bromide, 363  
     Gel filtration, 363  
   SDS-PAGE, 363  
   tissue distribution, 370–371  
   Western blotting, 363  
 Umbilical vein endothelial cells, 405(P18)  
 Unilateral ureteral obstruction (UUO), 61  
 Unmasked carbohydrate, 197–202  
 Uridine-5'-diphosphogalactose, 344  
 Uridine-5'-diphospho-N-acetylgalactosamine, 344  
 Urinary Tract Infection, 487  
 UTI. *See* Urinary Tract Infection  
 UV-vis, 149
- V**
- VCN. *See* *Vibrio cholerae* neuraminidase  
 Vein and arteries, 361  
 Ventricular assist device implantation effect on xylosyltransferase I activity, 414(P47)  
 Vesicle adhesion energy measurements, 166–168  
*Vibrio cholerae* neuraminidase, 451  
*Vicia villosa* agglutinin, 451  
 Viral antigens, 394(O5)  
 Virus

- influenza A, 471
  - influenza B, 471
    - promoted association, 475
  - Voltametry, cyclic, 487
  - VVA. *See* *Vicia villosa* agglutinin
- W
- WAC. *See* Weak affinity chromatography
  - Walker-Warburg syndrome, 5–6
  - Weak affinity chromatography, 149
  - Western blot analysis, 431
  - Western blotting, 363
    - of fluorescent NeuAc-labeled surface glycoproteins, 453
  - Wharton's jelly, 361
  - WWS. *See* Walker-Warburg syndrome
- X
- Xenopus laevis* oocyte cortical granule lectin
    - XL-35. *See* XL-35
  - XL-35, 443, 444
    - human homologs of, 445–446
    - mouse homologs of, 446, 448
    - other organisms, 449
  - X-lectins. *See* XL-35
  - XT I protein, 395(O9)
  - XT-I genes, 414(P46)
  - XT-II genes, 414(P46)
  - Xylosyl-glucose, 197–202
  - Xylosyltransferase I, 395(O9), 412(P39), 414(P47)
- Y
- Yeast
- Z
- Zebrafish
    - galectins in, 503–518
      - binding properties, 504–505
      - biochemical properties, 504
      - biological role in development and innate immunity, 503, 507–512
      - evolutionary aspects, 505–506
      - protein structure and gene organization, 505
      - subcellular localization and secretion, 506
    - HS6ST, 49
  - Zebrafish HS6ST, 49. *See also* *Drosophila* HS6ST
  - zHS6ST. *See* Zebrafish HS6ST
  - Zymography for MMP-2 activity detection, 430
- expression system, 78
- glycosyltransferase genes in, 75